|
시장보고서
상품코드
2049681
항류마티스제 시장 보고서 : 종류별, 약물 종류별, 투여 경로별, 유통 채널별, 지역별(2026-2034년)Anti-Rheumatics Market Report by Type, Drug Class, Route of Drug Administration, Distribution Channel, and Region 2026-2034 |
||||||
세계의 항류마티스제 시장 규모는 2025년에 676억 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 820억 달러에 달하고, 2026년부터 2034년까지 CAGR 2.10%로 성장할 것으로 예측했습니다. 고령화, 병원, 진료소 및 기타 의료 시설의 확대, 대형 제약사와 헬스케어 센터와의 제휴 확대 등이 시장 성장을 견인하는 주요 요인으로 작용하고 있습니다.
항류마티스제는 관절, 근육 및 결합조직에 영향을 미치는 질환을 치료하는 데 사용되는 약물입니다. 이는 염증, 통증, 뻣뻣함을 완화하고 질병의 진행을 늦추는 데 도움이 됩니다. 항류마티스제는 비스테로이드성 항염증제(NSAIDs), 질병조절형 항류마티스제(DMARDs), 생물학적 제제 등 다양한 종류가 있습니다. 이들 약제는 경구, 피하 또는 정맥으로 투여할 수 있습니다. 이들은 조직 손상과 염증을 유발하는 근본적인 메커니즘에 작용합니다. 일반적으로 철저한 진단을 통해 처방되며, 최적의 결과를 얻기 위해 병용하여 사용됩니다.
건강에 해로운 식습관과 운동 부족으로 인한 류마티스 질환의 유병률 증가는 효과적인 치료법에 대한 수요를 촉진하는 주요 요인 중 하나입니다. 또한, 나노입자 기반 캐리어, 서방형 캡슐 등 약물전달 시스템의 지속적인 개발로 항류마티스 약물의 효능과 편의성이 향상되고 있습니다. 이와 더불어, 원격의료 서비스의 확대로 질병 관리의 개선과 처방전 갱신이 용이해져 항류마티스 약물의 지속적인 사용이 촉진되고 있습니다. 또한, 신흥시장으로 의료시스템이 확대되면서 의료서비스가 취약한 계층도 항류마티스제를 쉽게 접할 수 있게 되었습니다. 또한, 유전체학 및 맞춤의료의 발전으로 보다 표적화된 치료가 가능해지면서 항류마티스 약물의 효능이 향상되고 있습니다.
항류마티스제 시장 동향 및 촉진요인:
고령화 진행
골관절염, 류마티스 관절염 등 관절 질환에 취약한 고령 인구의 증가는 시장 성장을 촉진하는 주요 요인 중 하나입니다. 또한, 노인들은 종종 여러 가지 건강 문제를 가지고 있으며, 이는 류마티스 질환을 악화시킬 수 있기 때문에 더 복잡하고 장기적인 치료 전략이 필요합니다. 또한, 각국 정부 당국과 의료 시스템도 이러한 수요를 인식하고 고령화 사회가 직면한 문제를 해결하기 위해 의료 예산을 증액하고 있습니다. 제약사들도 보다 효과적이고 안전한 항류마티스제 개발에 연구개발에 집중하고 있습니다. 그 결과, 이들 약물의 시장은 향후 몇 년 동안 크게 확대될 것으로 예상됩니다.
전략적 제휴 및 인수합병
제약회사와 헬스케어 시설 간의 전략적 제휴, 합병, 인수합병(M&A)의 증가도 시장 성장에 기여하는 또 다른 주요 요인입니다. 이러한 계약에는 종종 지식 공유 계약이 포함되어 있어 규제 장벽을 쉽게 극복하고 신약의 시장 출시 시간을 단축할 수 있습니다. 또한, 대형 제약사와 바이오테크 스타트업의 제휴 확대로 새로운 항류마티스 약물의 개발 및 상용화가 가속화되고 있습니다. 이와 더불어 보다 진보된 약제를 도입하기 위한 연구개발(R&D) 활동도 촉진되고 있습니다. 또한, 이러한 제휴는 그동안 미개척 시장으로 항류마티스제의 원활한 공급을 촉진하여 세계 시장 성장에 기여하고 있습니다.
조기 진단 및 예방에 대한 인식 제고
류마티스 관절염 질환의 조기 진단과 예방의 이점에 대한 개인들의 인식이 높아지면서 시장 성장을 견인하고 있습니다. 조기 진단을 통해 질병을 보다 효과적으로 관리할 수 있으며, 많은 경우 항류마티스 약물을 사용해야 합니다. 또한, 의료 교육을 촉진하는 소셜 미디어에 대한 사람들의 의존도가 높아지는 것도 시장에 긍정적인 영향을 미치고 있습니다. 또한 일부 국가의 행정 당국은 공중 보건 캠페인을 전개하고 있으며, 이는 시장에 유리한 전망을 가져오고 있습니다. 또한, 첨단 진단 도구의 개발로 의료진이 류마티스 질환을 조기에 발견할 수 있게 되었습니다. 이러한 적극적인 접근 방식은 항류마티스 약품에 대한 시장 수요를 증가시키고 있습니다. 왜냐하면, 적시에 개입하기 위해서는 증상 관리와 질병 조절을 위한 약물 치료가 필요하기 때문입니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 항류마티스제 시장
제6장 시장 내역 : 유형별
제7장 시장 내역 : 약물 종류별
제8장 시장 내역 : 투여 경로별
제9장 시장 내역 : 유통 채널별
제10장 시장 내역 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
KSM 26.06.10The global anti-rheumatics market size reached USD 67.6 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 82.0 Billion by 2034, exhibiting a growth rate (CAGR) of 2.10% during 2026-2034. The increasing aging population across the globe, expansion of hospitals, clinics, and other healthcare facilities, and the expanding partnerships between large pharmaceutical companies and healthcare centers are some of the major factors propelling the market growth.
Anti-rheumatics are medications used to treat diseases affecting the joints, muscles, and connective tissues. They help reduce inflammation, pain, and stiffness, and slow the progression of the disease. They are available in various classes, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and biologics. They can be administered orally, subcutaneously and intravenously into the body. They target the underlying mechanisms that lead to tissue damage and inflammation. They are generally prescribed after a thorough diagnosis and are used in combination for optimum results.
The rising prevalence of rheumatic diseases due to unhealthy dietary patterns and lack of physical activity represent one of the key factors catalyzing the demand for effective treatments. Additionally, continuous development in drug delivery systems, like nanoparticle-based carriers or time-release capsules, is enhancing the efficacy and convenience of anti-rheumatic medications. Apart from this, the growth of telehealth services is enabling better disease management and easier prescription refills, promoting consistent use of anti-rheumatic drugs. Furthermore, the expansion of healthcare systems into emerging markets is making anti-rheumatic medications more accessible to underserved populations. Moreover, advancements in genomics and personalized medicine are allowing for more targeted treatments and improving the effectiveness of anti-rheumatic medications.
ANTI-RHEUMATICS MARKET TRENDS/DRIVERS:
Rising aging population
The increasing aging population, which is more susceptible to joint disorders, such as osteoarthritis and rheumatoid arthritis, represents one of the key factors augmenting the market growth. Moreover, older populations often have multiple health conditions that can exacerbate rheumatic diseases, thus requiring more complex and long-term treatment strategies. Additionally, governing authorities and healthcare systems of various countries are recognizing this growing need and are increasing healthcare budgets to address the challenges of an aging society. Pharmaceutical companies are also focusing their research and development efforts on creating more effective and safer anti-rheumatic medications. As a result, the market for these drugs is expected to grow substantially in the coming years.
Strategic collaborations and mergers
The increasing number of strategic collaborations, mergers, and acquisitions (M&A) among pharmaceutical companies and healthcare facilities is another major factor contributing to the market growth. They often include knowledge-sharing agreements, making it easier to navigate regulatory hurdles and reducing the time-to-market for new medications. Additionally, the expanding partnerships between large pharmaceutical companies and biotech startups result in the faster development and commercialization of new anti-rheumatic drugs. Apart from this, it facilitates research and development (R&D) activities to introduce more advanced drugs. Furthermore, these collaborations promote an easy supply of anti-rheumatic drugs to reach previously untapped markets, contributing to global market growth.
Rising awareness about early diagnosis and prevention
The rising awareness among individuals about the benefits of early diagnosis and prevention of rheumatoid diseases is strengthening the growth of the market. Early diagnosis allows for more effective management of the disease, often requiring the use of anti-rheumatic drugs. Additionally, the increasing reliance of people on social media channels promoting medical education is positively influencing the market. Furthermore, the governing authorities of several countries are organizing public health campaigns, which is offering a favorable market outlook. Moreover, the development of advanced diagnostic tools has made it easier for healthcare professionals to identify rheumatic diseases at an early stage. This proactive approach enhances the market demand for anti-rheumatics, as timely intervention necessitates medication for symptom management and disease modification.
ANTI-RHEUMATICS INDUSTRY SEGMENTATION:
Breakup by Type:
- Prescription-based Drugs
- Over-the-Counter Drugs
Prescription-based drugs account for the majority of the market share
Breakup by Drug Class:
- Disease Modifying Anti-Rheumatics Drugs (DMARD's)
- Nonsteroidal Anti-Inflammatory Drugs (NSAID's)
- Corticosteroids
- Uric Acid Drugs
- Others
Disease modifying anti-rheumatics drugs (DMARD's) hold the largest share in the industry
Breakup by Route of Drug Administration:
- Oral
- Parenteral
- Others
Parenteral represents the leading market segment
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
Hospital pharmacies exhibit a clear dominance in the market
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
North America leads the market, accounting for the largest anti-rheumatics market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share since the region is a hub for pharmaceutical research and development (R&D). Additionally, North America, particularly the United States, has a well-established healthcare system equipped with state-of-the-art medical facilities. This superior infrastructure allows for the early diagnosis and comprehensive treatment of rheumatic diseases, which naturally leads to a higher demand for anti-rheumatic medications. Along with this, the widespread availability of specialized rheumatology clinics and medical professionals further drives the need for these drugs. Apart from this, the regulatory environment in North America, led by agencies like the U.S. Food and Drug Administration (FDA), is highly supportive of medical advancements. Furthermore, the increasing aging population in the region is driving the demand for anti-rheumatics.
COMPETITIVE LANDSCAPE:
Companies are investing heavily in the development of new anti-rheumatic drugs, targeting existing and emerging therapeutic mechanisms. Additionally, many companies are entering into partnerships, mergers, and acquisitions. These strategic collaborations often involve sharing technology, resources, and market channels. Apart from this, they are also focusing on expanding market access through various channels. This often involves launching products in new geographical markets, increasing production capacities, or diversifying supply chains to ensure more reliable distribution. Furthermore, various companies are using analytics to identify market trends, patient preferences, and treatment outcomes. Moreover, they are investing in educational programs for healthcare providers, patients, and the public.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca plc
- Biogen Inc.
- Bristol-Myers Squibb Company
- Celltrion Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Johnson & Johnsons
- Pfizer Inc.
- Sanofi SA
Key Questions Answered in This Report
- 1.What was the size of the global anti-rheumatics market in 2025?
- 2.What is the expected growth rate of the global anti-rheumatics market during 2026-2034?
- 3.What are the key factors driving the global anti-rheumatics market?
- 4.What has been the impact of COVID-19 on the global anti-rheumatics market?
- 5.What is the breakup of the global anti-rheumatics market based on the type?
- 6.What is the breakup of the global anti-rheumatics market based on the drug class?
- 7.What is the breakup of the global anti-rheumatics market based on the route of drug administration?
- 8.What is the breakup of the global anti-rheumatics market based on the distribution channel?
- 9.What are the key regions in the global anti-rheumatics market?
- 10.Who are the key players/companies in the global anti-rheumatics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Anti-Rheumatics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Prescription-based Drugs
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Over-the-Counter Drugs
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Drug Class
- 7.1 Disease Modifying Anti-Rheumatics Drugs (DMARD's)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAID's)
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Corticosteroids
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Uric Acid Drugs
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by Route of Drug Administration
- 8.1 Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Parenteral
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Distribution Channel
- 9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 E-Commerce
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 AbbVie Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Amgen Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 AstraZeneca plc
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Biogen Inc.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Bristol-Myers Squibb Company
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Celltrion Inc.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Eli Lilly and Company
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 F. Hoffmann-La Roche AG
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.9 Johnson & Johnsons
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Pfizer Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Sanofi SA
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.1 AbbVie Inc.
